The Korean journal of internal medicine

  • 제33권6호
  • /
  • Pages.1182-1193
  • /
  • 2018
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer

  • Jung, Yun Hwa (Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea) ;
  • Kim, Jae Young (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Jang, Yu Na (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Yoo, Sang Hoon (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Gyo Hui (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, Kang Min (Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Lee, In Kyu (Department of Surgery, College of Medicine, The Catholic University of Korea) ;
  • Chung, Su Mi (Department of Radiation Oncology, College of Medicine, The Catholic University of Korea) ;
  • Woo, In Sook (Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea)
  • 투고 : 2016.06.22
  • 심사 : 2017.04.02
  • 발행 : 2018.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Elderly patients (${\geq}80years$) with colorectal cancer (CRC) tend to avoid active treatment at the time of diagnosis despite of recent advances in treatment. The aim of this study was to determine treatment propensity of elderly patients aged ${\geq}80years$ with CRC in clinical practice and the impact of anticancer treatment on overall survival (OS). Methods: Medical charts of 152 elderly patients (aged ${\geq}80years$) diagnosed with CRC between 1998 and 2012 were retrospectively reviewed. Patients' clinical characteristics, treatment modalities received, and clinical outcome were analyzed. Results: Their median age was 82 years (range, 80 to 98). Of 152 patients, 148 were assessable for the extent of the disease. Eighty-two of 98 patients with localized disease and 28 of 50 patients with metastatic disease had received surgery or chemotherapy or both. Surgery was performed in 79 of 98 patients with localized disease and 15 of 50 patients with metastatic disease. Chemotherapy was administered in only 24 of 50 patients with metastatic disease. Patients who received anticancer treatment according to disease extent showed significantly longer OS compared to untreated patients (localized disease, 76.2 months vs. 15.4 months, p = 0.000; metastatic disease, 9.9 months vs. 2.6 months, p = 0.001). Along with anticancer treatment, favorable performance status (PS) was associated with longer OS in multivariate analysis of clinical outcome. Conclusions: Elderly patients aged ${\geq}80years$ with CRC tended to receive less treatment for metastatic disease. Nevertheless, anticancer treatment in patients with favorable PS was effective in prolonging OS regardless of disease extent.

키워드

참고문헌

  1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-117. https://doi.org/10.3322/caac.21220
  2. Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius B. Age-dependent improvement in median and longterm survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 2013;24:2354-2360. https://doi.org/10.1093/annonc/mdt197
  3. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 2015;26:463-476. https://doi.org/10.1093/annonc/mdu253
  4. Bojer AS, Roikjaer O. Elderly patients with colorectal cancer are oncologically undertreated. Eur J Surg Oncol 2015;41:421-425. https://doi.org/10.1016/j.ejso.2014.10.065
  5. Hardiman KM, Cone M, Sheppard BC, Herzig DO. Disparities in the treatment of colon cancer in octogenarians. Am J Surg 2009;197:624-628. https://doi.org/10.1016/j.amjsurg.2008.12.018
  6. Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev 2006;32:1-8.
  7. Nakamura T, Sato T, Miura H, et al. Feasibility and outcomes of surgical therapy in very elderly patients with colorectal cancer. Surg Laparosc Endosc Percutan Tech 2014;24:85-88. https://doi.org/10.1097/SLE.0b013e3182a83477
  8. Gurevitch AJ, Davidovitch B, Kashtan H. Outcome of right colectomy for cancer in octogenarians. J Gastrointest Surg 2009;13:100-104. https://doi.org/10.1007/s11605-008-0643-3
  9. Yap R, Oliva K, Wilkins S, McMurrick PJ. Colorectal cancer surgery in the very elderly: nonagenarians. Dis Colon Rectum 2016;59:501-507. https://doi.org/10.1097/DCR.0000000000000578
  10. Iversen LH, Pedersen L, Riis A, Friis S, Laurberg S, Sorensen HT. Age and colorectal cancer with focus on the elderly: trends in relative survival and initial treatment from a Danish population-based study. Dis Colon Rectum 2005;48:1755-1763. https://doi.org/10.1007/s10350-005-0107-8
  11. Nascimbeni R, Di Fabio F, Di Betta E, Salerni B. The changing impact of age on colorectal cancer surgery: a trend analysis. Colorectal Dis 2009;11:13-18. https://doi.org/10.1111/j.1463-1318.2008.01491.x
  12. Kumar R, Jain K, Beeke C, et al. A population-based study of metastatic colorectal cancer in individuals aged $\geq$ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. Cancer 2013;119:722-728. https://doi.org/10.1002/cncr.27802
  13. Doat S, Thiebaut A, Samson S, Ricordeau P, Guillemot D, Mitry E. Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. Eur J Cancer 2014;50:1276-1283. https://doi.org/10.1016/j.ejca.2013.12.026
  14. McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist 2008;13:876-885. https://doi.org/10.1634/theoncologist.2008-0061
  15. Seal BS, Sullivan SD, Ramsey SD, et al. Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. BioDrugs 2014;28:229-236. https://doi.org/10.1007/s40259-013-0073-y
  16. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616. https://doi.org/10.1200/JCO.2002.04.123
  17. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292. https://doi.org/10.1200/JCO.2001.19.8.2282
  18. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23:3104-3111. https://doi.org/10.1200/JCO.2005.06.035
  19. Kroep JR, van Werkhoven E, Polee M, et al. Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer: TLC study. J Geriatr Oncol 2015;6:307-315. https://doi.org/10.1016/j.jgo.2015.05.004
  20. Sanoff HK, Goldberg RM. How we treat metastatic colon cancer in older adults. J Geriatr Oncol 2013;4:295-301. https://doi.org/10.1016/j.jgo.2013.07.007
  21. Bradley CJ, Yabroff KR, Warren JL, Zeruto C, Chawla N, Lamont EB. Trends in the treatment of metastatic colon and rectal cancer in elderly patients. Med Care 2016;54:490-497. https://doi.org/10.1097/MLR.0000000000000510
  22. Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol 2016;27:121-127. https://doi.org/10.1093/annonc/mdv491
  23. Kawakami K, Nakamoto E, Yokokawa T, et al. Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence 2015;9:561-567.
  24. Seal BS, Anderson S, Shermock KM. Factors associated with adherence rates for oral and intravenous anticancer therapy in commercially insured patients with metastatic colon cancer. J Manag Care Spec Pharm 2016;22:227-235.
  25. Ohnishi T, Kanoh T, Kimura Y, et al. Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis. Gan To Kagaku Ryoho 2007;34:623-625.
  26. Jung YH, Lee WJ, Byeon JH, Lee IK, Han CW, Woo IS. Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients. Korean J Intern Med 2017;32:926-929. https://doi.org/10.3904/kjim.2015.049
  27. Romiti A, Onesti CE, Roberto M, et al. Continuous, lowdose capecitabine for patients with recurrent colorectal cancer. Med Oncol 2015;32:54. https://doi.org/10.1007/s12032-015-0496-z
  28. Rosati G, Aprile G, Cardellino GG, Avallone A. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 2016;7:134-141. https://doi.org/10.1016/j.jgo.2016.01.006
  29. Sclafani F, Cunningham D. Bevacizumab in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 2014;5:78-88. https://doi.org/10.1016/j.jgo.2013.08.006

피인용 문헌

  1. Benefit of intensive chemotherapy for elderly patients aged 80 years or older with metastatic colorectal cancer: a state-wide multicenter cohort study vol.26, pp.7, 2021, https://doi.org/10.1007/s10147-021-01909-9
  2. Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies vol.38, pp.8, 2018, https://doi.org/10.1007/s40266-021-00869-z